These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24689722)

  • 1. Biosimilar therapy for inflammatory bowel disease.
    Avendaño-Solá C; Panés J; Calvo G
    Rev Esp Enferm Dig; 2014 Jan; 106(1):65-6. PubMed ID: 24689722
    [No Abstract]   [Full Text] [Related]  

  • 2. Author´s answer: Biosimilar therapy for inflammatory bowel disease.
    Argüelles-Arias F; Barreiro-de-Acosta M; Carballo F; Hinojosa J; Tejerina T
    Rev Esp Enferm Dig; 2014 Jan; 106(1):67-8. PubMed ID: 24689723
    [No Abstract]   [Full Text] [Related]  

  • 3. Biosimilar and Originator Product in Inflammatory Bowel Diseases: Mind the Gap?
    Kotze PG; Danese S
    Curr Med Chem; 2019; 26(2):246-247. PubMed ID: 30907307
    [No Abstract]   [Full Text] [Related]  

  • 4. Biosimilar therapies in inflammatory bowel disease: should we care about patient profile?
    Fiorino G; Fazio M; Danese S
    Expert Rev Clin Immunol; 2016; 12(4):361-3. PubMed ID: 26752540
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of healthcare providers in accompanying biosimilars in inflammatory bowel diseases.
    Felice C; Pugliese D; Armuzzi A
    Expert Opin Biol Ther; 2019 Oct; 19(10):967-969. PubMed ID: 30616459
    [No Abstract]   [Full Text] [Related]  

  • 6. Belgian IBD research group (BIRD) position statement 2017 on the use of biosimilars in inflammatory bowel diseases (IBD).
    Franchimont D; Ferrante M; Louis E; De Vos M; Dewit O; Van Hootegem P; Moreels T; Liefferinckx C; Bossuyt P; Baert F; Rahier JF; Vermeire S
    Acta Gastroenterol Belg; 2018; 81(1):49-53. PubMed ID: 29562378
    [No Abstract]   [Full Text] [Related]  

  • 7. Biosimilars in inflammatory bowel disease.
    Moore GT
    Med J Aust; 2016 Oct; 205(7):294-5. PubMed ID: 27681963
    [No Abstract]   [Full Text] [Related]  

  • 8. Biosimilar medicines in inflammatory bowel disease.
    Moum B; Lundin KE
    Tidsskr Nor Laegeforen; 2014 Apr; 134(8):819-20. PubMed ID: 24780979
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: The Explosion of Biosimilars in Immune Mediated Chronic Inflammatory Diseases.
    Araujo FC; Fonseca JE; Goncalves J
    Curr Pharm Des; 2017; 23(44):6731-6732. PubMed ID: 29534674
    [No Abstract]   [Full Text] [Related]  

  • 10. ECCO Position Statement on the Use of Biosimilars for Inflammatory Bowel Disease-An Update.
    Danese S; Fiorino G; Raine T; Ferrante M; Kemp K; Kierkus J; Lakatos PL; Mantzaris G; van der Woude J; Panes J; Peyrin-Biroulet L
    J Crohns Colitis; 2017 Jan; 11(1):26-34. PubMed ID: 27927718
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of biosimilars in inflammatory bowel diseases: A survey among the clinicians members of the Italian Group for the Study of Inflammatory Bowel Disease (IGIBD).
    Viscido A; Buda A; Caprioli F; Principi M; Daperno M; Armuzzi A
    Dig Liver Dis; 2020 Aug; 52(8):928-930. PubMed ID: 32616462
    [No Abstract]   [Full Text] [Related]  

  • 12. The biosimilar road in inflammatory bowel disease: the right way?
    Fiorino G; Danese S
    Best Pract Res Clin Gastroenterol; 2014 Jun; 28(3):465-71. PubMed ID: 24913385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
    Argüelles Arias F; Hinojosa Del Val J; Vera Mendoza I
    Rev Esp Enferm Dig; 2018 Jun; 110(6):407. PubMed ID: 29527903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
    Mak JW; Sung JJ
    J Gastroenterol Hepatol; 2019 Aug; 34(8):1269-1270. PubMed ID: 31456235
    [No Abstract]   [Full Text] [Related]  

  • 15. A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.
    Farkas K; Molnár T
    Immunotherapy; 2018 Feb; 10(2):107-117. PubMed ID: 29124994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab biosimilar in inflammatory bowel disease.
    Fiorino G; Allocca M; Danese S
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):775-776. PubMed ID: 34388361
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenges of modern day transition care in inflammatory bowel disease: From inflammatory bowel disease to biosimilars.
    Hakizimana A; Ahmed I; Russell R; Wright M; Afzal NA
    World J Gastroenterol; 2017 Jul; 23(25):4473-4479. PubMed ID: 28740335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in IBD: hope or expectation?
    Gecse KB; Khanna R; van den Brink GR; Ponsioen CY; Löwenberg M; Jairath V; Travis SP; Sandborn WJ; Feagan BG; D'Haens GR
    Gut; 2013 Jun; 62(6):803-7. PubMed ID: 23503043
    [No Abstract]   [Full Text] [Related]  

  • 19. The Experience with Biosimilars of Infliximab in Inflammatory Bowel Disease.
    Avila-Ribeiro P; Fiorino G; Danese S
    Curr Pharm Des; 2017; 23(44):6759-6769. PubMed ID: 29205114
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of efficacy and safety of the switch from infliximab original to infliximab biosimilar (CT-P13) in patients with inflammatory bowel disease.
    Guerra Veloz MF; Argüelles-Arias F; Castro Laria L; Maldonado Pérez B; Benítez Roldan A; Perea Amarillo R; Merino Bohórquez V; Calleja MA; Caunedo Álvarez Á; Vilches Arenas Á
    World J Gastroenterol; 2018 Dec; 24(46):5288-5296. PubMed ID: 30581277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.